Mike K. Palmer

1.9k citations

26 papers · 1.4k indexed · 1 hit paper · h-index 17

Surgery top 5%
Cardiology and Cardiovascular Medicine top 5%
Endocrinology, Diabetes and Metabolism top 5%
Pulmonary and Respiratory Medicine top 10%
Economics and Econometrics top 5%

Co-authors: Stephen J. Nicholls Philip J. Barter Michiel L. Bots Joel S. Raichlen Gunnar Brandrup‐Wognsen Gregory W. Evans Diederick E. Grobbee Daniel H. O’Leary
Topics: Lipoproteins and Cardiovascular Health (11 papers)Cardiovascular Health and Disease Prevention (10 papers)Diabetes, Cardiovascular Risks, and Lipoproteins (8 papers)
Cited by: Cardiology and Cardiovascular Medicine Endocrinology, Diabetes and Metabolism Surgery
Journals: JAMA Circulation Cancer
Partner nations: United Kingdom United States Netherlands

In The Last Decade

Mike K. Palmer

26 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals With Subclinical Atherosclerosis

2007 510 citations John R. Crouse, Joel S. Raichlen et al. JAMA profile →

Peers

Countries citing papers authored by Mike K. Palmer

Since Specialization

Citations

This map shows the geographic impact of Mike K. Palmer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mike K. Palmer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mike K. Palmer more than expected).

Fields of papers citing papers by Mike K. Palmer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mike K. Palmer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mike K. Palmer. The network helps show where Mike K. Palmer may publish in the future.

Co-authorship network of co-authors of Mike K. Palmer

This figure shows the co-authorship network connecting the top 25 collaborators of Mike K. Palmer. A scholar is included among the top collaborators of Mike K. Palmer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mike K. Palmer. Mike K. Palmer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study 2013 ·Atherosclerosis ·Christie M. Ballantyne,Ron C. Hoogeveen,Joe L. Raya,Valerie A. Cain,Mike K. Palmer,Björn W. Karlson	36
2	Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dl or ≥50% reduction in high-risk patients: Results from VOYAGER 2013 ·Atherosclerosis ·Björn W. Karlson,Stephen J. Nicholls,Pia Lundman,Mike K. Palmer,Philip J. Barter	18
3	Effect of Rosuvastatin on the Echolucency of the Common Carotid Intima-Media in Low-Risk Individuals: The METEOR Trial 2012 ·Journal of the American Society of Echocardiography ·Lars Lind,Sanne A. E. Peters,Hester M. den Ruijter,Mike K. Palmer,Diederick E. Grobbee,John R. Crouse,Daniel H. O’Leary,Gregory W. Evans,Joel S. Raichlen,Michiel L. Bots	19
4	Multiple imputation of missing repeated outcome measurements did not add to linear mixed-effects models 2012 ·Journal of Clinical Epidemiology ·Sanne A. E. Peters,Michiel L. Bots,Hester M. den Ruijter,Mike K. Palmer,Diederick E. Grobbee,John R. Crouse,Daniel H. O’Leary,Gregory W. Evans,Joel S. Raichlen,Karel G.M. Moons,Hendrik Koffijberg	126
5	Sample size requirements in trials using repeated measurements and the impact of trial design 2012 ·Current Medical Research and Opinion ·Sanne A. E. Peters,Mike K. Palmer,Hester M. den Ruijter,Diederick E. Grobbee,John R. Crouse,Daniel H. O’Leary,Gregory W. Evans,Joel S. Raichlen,Michiel L. Bots	8
6	Effect of number of ultrasound examinations on the assessment of carotid intima–media thickness changes over time: the example of the METEOR study 2011 ·Journal of Hypertension ·Sanne A. E. Peters,Mike K. Palmer,Diederick E. Grobbee,John R. Crouse,Gregory W. Evans,Joel S. Raichlen,Michiel L. Bots	7
7	The Use of Plaque Score Measurements to Assess Changes in Atherosclerotic Plaque Burden Induced by Lipid-Lowering Therapy Over Time: The METEOR Study 2011 ·Journal of Atherosclerosis and Thrombosis ·Sanne A. E. Peters,Soner Doğan,Rudy Meijer,Mike K. Palmer,Diederick E. Grobbee,John R. Crouse,Daniel H. O’Leary,Gregory W. Evans,Joel S. Raichlen,Michiel L. Bots	20
8	Extensive or Restricted Ultrasound Protocols to Measure Carotid Intima-Media Thickness: Analysis of Completeness Rates and Impact on Observed Rates of Change Over Time 2011 ·Journal of the American Society of Echocardiography ·Sanne A. E. Peters,Hester M. den Ruijter,Mike K. Palmer,Diederick E. Grobbee,John R. Crouse,Daniel H. O’Leary,Gregory W. Evans,Joel S. Raichlen,Michiel L. Bots	19
9	Algorithms to measure carotid intima–media thickness in trials 2011 ·Journal of Hypertension ·Soner Doğan,Y. Plantinga,John R. Crouse,Gregory W. Evans,Joel S. Raichlen,Daniel H. O’Leary,Mike K. Palmer,Diederick E. Grobbee,Michiel L. Bots	19
10	Does baseline carotid intima–media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima–media thickness progression? The METEOR study 2010 ·European Journal of Cardiovascular Prevention & Rehabilitation ·John R. Crouse,Michiel L. Bots,Gregory W. Evans,Mike K. Palmer,Daniel H. O’Leary,Diederick E. Grobbee,Joel S. Raichlen	10
11	Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER) 2009 ·The American Journal of Cardiology ·Stephen J. Nicholls,Gunnar Brandrup‐Wognsen,Mike K. Palmer,Philip J. Barter	188
12	A Primer on Screening Data Management 2009 ·SLAS DISCOVERY ·Mike K. Palmer,Andreas Kremer,Georg C. Terstappen	1
13	Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database 2009 ·Journal of Lipid Research ·Philip J. Barter,Gunnar Brandrup‐Wognsen,Mike K. Palmer,Stephen J. Nicholls	195
14	Toxic epidermal necrolysis and neutropaenia: Complications of omeprazole 2009 ·Australasian Journal of Dermatology ·Avnesh S. Thakor,(unknown),(unknown),(unknown),Mike K. Palmer,(unknown)	15
15	Abstract 194: Rosuvastatin Reduces Progression of Carotid Atherosclerosis within 12 Months of Treatment: The METEOR Trial 2007 ·Circulation ·Michiel L. Bots,Joel S. Raichlen,Gregory W. Evans,Mike K. Palmer,Daniel H. O’Leary,Diederick E. Grobbee,John R. Crouse	2
16	Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals With Subclinical Atherosclerosisbreakdown → 2007 ·JAMA ·John R. Crouse,Joel S. Raichlen,Ward A. Riley,Gregory W. Evans,Mike K. Palmer,Daniel H. O’Leary,Diederick E. Grobbee,Michiel L. Bots,for the Mexican Nephrology Collaborative Study Group	510
17	Carotid intima-media thickness in low-risk individuals with asymptomatic atherosclerosis: baseline data from the METEOR study 2007 ·Current Medical Research and Opinion ·John R. Crouse,Diederick E. Grobbee,Daniel H. O’Leary,Michiel L. Bots,Gregory W. Evans,Mike K. Palmer,Ward A. Riley,Joel S. Raichlen,(unknown)	19
18	Cerebellar neurotransmission in attention-deficit/hyperactivity disorder: Does dopamine neurotransmission occur in the cerebellar vermis? 2006 ·Journal of Neuroscience Methods ·Paul E.A. Glaser,(unknown),Richard Grondin,Clelland R. Gash,Mike K. Palmer,F. Xavier Castellanos,Greg A. Gerhardt	31
19	Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin in Subclinical Atherosclerosis—The Rationale and Methodology of the METEOR Study 2004 ·Cardiovascular Drugs and Therapy ·John R. Crouse,Diederick E. Grobbee,Daniel H. O’Leary,Michiel L. Bots,Gregory W. Evans,Mike K. Palmer,Ward A. Riley,Joel S. Raichlen	65
20	Intermittent high-dose cyclophosphamide with and without prednisolone. A study of the relationships between toxicity, response and survival in metastatic lung cancer 1982 ·Cancer ·Nicholas Thatcher,John Wagstaff,P M Wilkinson,Mike K. Palmer,Derek Crowther	20

About Mike K. Palmer

Mike K. Palmer is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Biochemistry, having authored 26 papers that have together received 1.4k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (11 papers), Cardiovascular Health and Disease Prevention (10 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (8 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (530 citations), Endocrinology, Diabetes and Metabolism (344 citations) and Surgery (745 citations). Mike K. Palmer has collaborated with scholars based in United Kingdom, United States and Netherlands. Frequent co-authors include Stephen J. Nicholls, Philip J. Barter, Michiel L. Bots, Joel S. Raichlen, Gunnar Brandrup‐Wognsen, Gregory W. Evans, Diederick E. Grobbee, Daniel H. O’Leary, Ward A. Riley and John R. Crouse. Their work appears in journals such as JAMA, Circulation and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact